IL6 and diabetic kidney disease: Therefore, in comparison to global inhibition of IL-6 or simply inhibition of the IL-6 trans-pathway, developing drugs that modulate the balance between IL-6 classical and trans-signaling pathways may be a more rational therapeutic strategy for DKD.